Key facts
- This page summarizes Brendan Smith's Form 4 filing for CRISPR Therapeutics AG (CRSP).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 Feb 2023, 16:41.
Brendan Smith - 18 Feb 2023 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CRSP
- Reported as of
- 18 Feb 2023
- Net transaction value
- -$67,178
- SEC form
- 4
- Accepted by SEC
- 22 Feb 2023, 16:41:41 UTC
- Prior SEC filing
- 18 Oct 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth Ryland Waldinger, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Brendan Smith filed Form 4 for CRISPR Therapeutics AG (CRSP) on 22 Feb 2023.
Change
- Previous filing in this sequence was filed on 18 Oct 2022.
- Current net transaction value: -$67,178.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRSP
transaction
Common Shares
Options Exercise
- Transaction value
- Shares
- +3,825
- Change %
- +145%
- Price
- Shares after
- 6,464
- Date
- 18 Feb 2023
- Ownership
- Direct
- Footnotes
- F1
CRSP
transaction
Common Shares
Tax liability
- Transaction value
- $67,178
- Shares
- -1,392
- Change %
- -22%
- Price
- $48.26
- Shares after
- 5,072
- Date
- 21 Feb 2023
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRSP
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -3,825
- Change %
- -25%
- Price
- Shares after
- 11,475
- Date
- 18 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 3,825
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
Footnote F2
Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
Footnote F3
This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.